search
Back to results

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Primary Purpose

Advanced Cancer

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TST001
Oxaliplatin
Capecitabine
Paclitaxel
Gemcitabine
Cisplatin
Nivolumab
Sponsored by
Suzhou Transcenta Therapeutics Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

The one who meet all inclusion criteria can be enrolled into the trial:

  1. Sign Informed Consent Form voluntarily. Understand the study and be willing to follow and be able to complete all trial procedures;
  2. Male or female aged at 18-75 (inclusive) years when ICF is signed;
  3. Suffer from advanced unresectable or metastatic malignant local solid tumors confirmed by histological diagnosis and meet the criteria of the enrolled group as follows:

    Part I: Mono-therapy dose escalation and expansion study:

    Mono-therapy dose escalation study: The subjects for whom no standard treatment regimens are available or who is intolerable to standard treatments.

    Mono-therapy dose expansion study: The subjects with positive CDLN18.2 expression in tumor tissue (which is defined as ≥40% tumor cells showing CLDN18.2 membrane dye ≥2+ through immunohistochemistry (IHC) test by the central laboratory) confirmed by the central laboratory at enrollment. There are 2 groups in Part I as follow:

    Group A: The subjects with G/GEJ adenocarcinoma for whom no standard therapy regimens are available currently or who are intolerable to standard therapy regimens; Group B: The subjects with other malignant tumors (including but not limited to ductal adenocarcinoma of pancreas, bile duct carcinoma, lung cancer, ovarian carcinoma and other malignant solid tumors) for whom no standard therapy regimens are available currently or who are intolerable to standard therapy regimens; Part II: Dose escalation and expansion study of combination medication

    Dose escalation study of combination medication (dose escalation part):

    Group C: The subjects with HER2 negative G/GEJ adenocarcinoma without previous systemic chemotherapy. The subjects who have completed neoadjuvant chemotherapy or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study are allowed to be enrolled.

    Group D: The subjects with G/GEJ adenocarcinoma at least with previous first-line systemic chemotherapy;

    Dose expansion study of combination medication (dose expansion part):

    The subjects with CDLN18.2 positive solid tumors (which is defined as ≥40% tumor cells showing CLDN18.2 membrane dye≥2+ through immunohistochemistry (IHC) test by the central laboratory) confirmed by the central laboratory will be enrolled.

    Group C: The subjects with HER2 negative G/GEJ adenocarcinoma without previous systemic chemotherapy. The subjects who have completed neoadjuvant chemotherapy or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study are allowed to be enrolled.

    Group D: The subjects with G/GEJ adenocarcinoma at least with previous first-line systemic chemotherapy; During the study, additional groups for the treatment of other solid tumors might be added according to the available clinical and pre-clinical study data (the inclusion criteria is to be determined).

  4. ECOG score 0-1;
  5. Expected survival ≥ 3 months;
  6. The results of the laboratory examination at screening must meet all the following criteria:

    Absolute neutrophil count (ANC) ≥ 1.5×109/L; Absolute count (WBC) ≥ 2.5×109/L; Platelets ≥ 100×109/L; Haemoglobin ≥ 9 g/dL; International normalized ratio (INR) ≤ 1.5 times Upper Limit of Normal (ULN) / or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN (for the test without anticoagulant); INR ≤ 2.5 times ULN / or APTT ≤ 2.5 times ULN (for the test with anticoagulant); Total Bilirubin ≤ 1.5 times ULN; AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for the subjects with hepatic cancer or metastases to liver); Albumin ≥ 3.0 g/L; Serum creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60 ml/min (creatinine clearance rate will be calculated by Cock-croft-Gault formula);

  7. Male and female of childbearing age should agree to take effective contraception measures (refer to Appendix 3. Contraception) from signing ICF till 3 months after the last dose; Blood β-HCG test for women of childbearing age within 70 hours prior to the initial dosing must be negative;
  8. (For dose expansion study only) There must be at least one assessable lesion conforming to the definition in RECIST v1.1;

Exclusion Criteria:

The subjects who meet any one of the following criteria cannot participate in the study:

  1. The subjects with advanced unresectable or metastatic local G/GEJ adenocarcinoma who are supposed to be enrolled into the combination therapy group with CAPOX have previously received systemic chemotherapy. The subjects will be eligible provided that they have completed neoadjuvant chemotherapy or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study; The subjects with advanced unresectable or metastatic local G/GEJ adenocarcinoma who are supposed to be enrolled into the combination therapy with paclitaxel have previously received paclitaxel treatment.
  2. The subjects who received radiotherapy within 4 weeks prior to the initial dosing of the investigational drug (the subjects who received local radiotherapy for bone metastases treatment with the radiotherapy related AE resolved to ≤ Grade 1 will be eligible);
  3. The subjects who received other anti-tumor medication or radiotherapy within 4 weeks prior to the initial dosing of the investigational drug; The medication (such as Zoledronic Acid) for bone metastases related events will not influence on the enrollment.
  4. The subjects who received major surgery (exclusive of aspiration biopsy) within 8 weeks prior to the initial dosing of the investigational drug, or who are expected to undergo major surgery, or who are in the conditions such as severe unhealed wound, trauma, ulcer.
  5. The subjects who received the treatment with CLDN18.2 monoclonal antibody or CLDN-18.2CART;
  6. The subjects who have previous serious allergic reactions, or are intolerable to the known component of TST001 or other monoclonal antibodies (including humanized or chimeric antibodies);
  7. The subjects who are known to have immediate or delayed hypersensitivity to, be intolerable to or be forbidden from any component of the investigational drugs;
  8. The subjects who have previous serious allergic reaction or intolerance to any component of CAPOX or taxane drugs;
  9. The subjects who manifest the symptoms of brain or leptomeningeal metastases;

    The subjects with central nerve system (CNS) metastasis who meets the following conditions can be enrolled:

    The subjects with brain metastasis who are naive to any treatment and have no symptom, or who are in progressive free status persisting for at least 8 weeks after treatment demonstrated by imaging data and do not require hormone or anti epilepsy treatment at least within 8 weeks;

  10. The subjects suffering from body cavity effusion (hydrothorax, ascites and pericardial effusion) that requires local treatment or repeated drainage and is not well controlled at the discretion of the investigator;
  11. (For dose expansion study only) The subjects suffering from co-existent malignant tumors. (The following tumor history at 5 years ago that has been cured will not influence on the enrollment: non-melasma, skin carcinoma, in situ cancer or non-invasive tumors.)
  12. The adverse reactions caused by previous treatment have not resolved to ≤ Grade 1 as per CTCAE v5.0 (exclusive of alopecia and anaemia) before the initial dosing of the investigational drug. If the adverse reaction has no clinical influence, the Sponsor and investigator will decide whether the subject can be enrolled in the study after discussion.
  13. The subjects who received growth factor, transfusion or other blood products in treatment of anaemia or decreased platelet within 14 days before screening;
  14. The subjects who experienced clinically significant cardiac diseases within 6 months before the initial dosing of the investigational drug, including:

    i. Myocardial infarction, ii. Unstable angina pectoris, iii. Cerebrovascular accident or iv. Other acute and uncontrollable cardiac diseases; Clinically significant ventricular arrhythmia history (such as persisting ventricular tachycardia, ventricular fibrillation and torsade de pointes); New York Heart Association (NYHA) Class III or IV congestive cardiac failure; QTc ≥470 (female) or QTc ≥450 (male) or medical history or family history of congenital long-QT syndrome ; The subjects with heart rhythm disorders who requires the treatment with antiarrhythmic drugs (The subjects who suffer from atrial fibrillation with heart rate controllable more than 1 month before the initial dosing of the investigational drug will be eligible);

  15. . The subjects who are known to have dihydropyrimidine dehydrogenase (DPD) deficiency. (Note: DPD deficiency screening should be performed according to local standard.) (The screening will be performed only in the subjects receiving CAPOX.)
  16. The subjects who experienced gastric haemorrhage recently or have the risk of gastric haemorrhage or gastric perforation demonstrated by evidences will be excluded from the study at the discretion of the investigator. The subjects suffering from obstruction pyloric and persistent repeated vomiting;
  17. The subjects who are known to have > Grade 1 peripheral sensory neuropathy, unless a lack of deep tendon reflexes is the only neurological abnormality.
  18. The subjects suffering from serious or uncontrollable gastro-intestinal tract bleed;
  19. The subjects suffering from active infection requiring systemic treatment;
  20. The subjects who have HIV infection history or positive HIV viral test;
  21. The subjects who are known to have the history of hepatitis C or chronic active hepatitis B;

    Except for:

    HBV virus carriers or the subjects with hepatitis B infection that is stable after medications (HBV-DNA titer should be no more than 1000 copies [cps]/mL or 200 IU/mL) The subjects with hepatitis C infection that is stable after medications (HCV-RNA test negative)

  22. The subjects suffering from active autoimmune disorders who required systemic immunosuppressive therapy within the past 2 years;
  23. The subjects who received systemic immunosuppressive therapy including glucocorticoid within 2 weeks before the initial dosing of the investigational drug; The subjects will be allowed to use hydrocortisone or similar drugs at physiologically alternative dose;
  24. Pregnant or lactating women;
  25. The subject with other conditions (such as psychological, geographic or medical conditions) that do not allow them to follow the study schedule and follow-up procedures. Or the subjects who are unsuitable to be enrolled into the study at the discretion of the investigator.

Sites / Locations

  • The First Affiliated Hospital of Bengbu Medical CollegeRecruiting
  • Beijing Cancer HospitalRecruiting
  • Beijing Friendship Hospital, Capital Medical UniversityRecruiting
  • Peking Union Medical College Hospital
  • Peking University International Hospital
  • The First Affiliated Hospital of Chongqing Medical UniversityRecruiting
  • Fujian Cancer HospitalRecruiting
  • Fujian Medical University Union HospitalRecruiting
  • The First Affiliated Hospital of Xiamen UniversityRecruiting
  • The Sixth Affiliated Hospital of Sun Yat-sen UniversityRecruiting
  • The People's Hospital of Guangxi Zhuang Autonomous Region
  • Hainan Provincial People's HospitalRecruiting
  • The First Affiliated Hospital of Zhengzhou UniversityRecruiting
  • Harbin Medical University Cancer HospitalRecruiting
  • Henan Cancer HospitalRecruiting
  • Hubei Cancer HospitalRecruiting
  • Zhongnan Hospital of Wuhan UniversityRecruiting
  • Hunan Cancer HospitalRecruiting
  • Xiangya Hospital, Central South UniversityRecruiting
  • Suzhou Municipal HospitalRecruiting
  • The Second Affiliated Hospital of Soochow UniversityRecruiting
  • Xuzhou Central HospitalRecruiting
  • The Second Affiliated Hospital of Nanchang UniversityRecruiting
  • Jilin Cancer HospitalRecruiting
  • The First Hospital of Jilin UniversityRecruiting
  • The First Affiliated Hospital of Jinzhou Medical UniversityRecruiting
  • Liaoning Cancer Hospital & InstituteRecruiting
  • The First Hospital of China Medical UniversityRecruiting
  • Jinan Central HospitalRecruiting
  • Linyi Cancer HospitalRecruiting
  • The Affiliated Hospital of Qingdao UniversityRecruiting
  • Fudan University Shanghai Cance CenterRecruiting
  • Zhongshan Hospital Fudan UniversityRecruiting
  • West China Hospital, Sichuan UniversityRecruiting
  • Sichuan Cancer HospitalRecruiting
  • Tianjin Medical University Cancer Institute & HospitalRecruiting
  • Tianjin Medical University General HospitalRecruiting
  • First Affiliated Hospital of Zhejiang UniversityRecruiting
  • The Second Affiliated Hospital of Zhejiang University School of MedicineRecruiting
  • Zhejiang Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

dose escalation Q2W

dose escalation Q3W

Cohort A

Cohort B

Cohort E

Cohort C

Cohort D

Cohort F

Cohort G

Cohort H (TST001 plus nivolumab)

Arm Description

Dosed every 2 weeks IV with TST001, multiple dose levels will be tested.

Dosed every 3 weeks IV with TST001, multiple dose levels will be tested.

Participants with gastric or gastroesophageal junction cancers and CLDN18.2 expression

Participants with ductal adenocarcinoma of pancreas and CLDN18.2 expression and CLDN18.2 expression

Participants with advanced or metastatic solid tumors other than G/GEJ adenocarcinoma and CLDN18.2 expression

Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma

Participants with locally advanced or metastatic G/GEJ adenocarcinoma

Participants with locally advanced or metastatic biliary tract cancer

Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma

Participants with locally advanced or metastatic G/GEJ adenocarcinoma

Outcomes

Primary Outcome Measures

Participant Safety as characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0).
An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Maximum Tolerated Dose (MTD)
The maximum tolerated dose (MTD) is commonly estimated to be the maximum dose that can be determined through DLT of two among 6 subjects administered with TST001 Q2W in 28 days cycles.
Maximum Tolerated Dose (MTD)
The maximum tolerated dose (MTD) is commonly estimated to be the maximum dose that can be determined through DLT of two among 6 subjects administered with TST001 once every 3 weeks in 21 days cycles.
Recommended Phase 2 Dose (RP2D)
The RP2D will be determined during the dose expansion stage of the study. RP2D will be determined using available safety and efficacy data.
The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 Q2W in 28 days cycles during observation period
DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 once every 3 weeks in 21 days cycles during observation period
DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Safety and Tolerability of TST001 in combination with other therapies, e.g. CAPOX, paclitaxel, GP, nivolumab as characterized by frequency and severity of adverse events
Characterization of TST001 + CAPOX safety profile including frequency and severity of adverse events that are related to treatment.

Secondary Outcome Measures

Area under plasma concentration vs time curve (AUC) for TST001
Changes in AUC over time in participants with TST001.
Peak plasma concentration (Cmax) for TST001
Cmax is the maximum plasma concentration.
Time to maximum observed plasma concentration (Tmax)
Tmax is the time in hrs/days it takes to reach Cmax after dosing with TST001
Terminal elimination half life (t1/2)
Time for the plasma level of TST001 to decrease b y 1/2 during the terminal elimination phase.
Immunogenicity
by measurement of Incidence of anti-drug antibodies (ADA)
Objective response rate (ORR)
as measured by RECIST 1.1
Duration of Response (DOR)
DOR is defined as the time from the date of the first response CR (complete remission)/PR (partial remission) (whichever is first recorded) to the date of radiographical progression/death or date of censoring.
Disease Control Rate
DCR: CR+PR+SD
Progression free survival (PFS) and OS
as measured by RECIST v1.1

Full Information

First Posted
July 23, 2020
Last Updated
March 27, 2023
Sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT04495296
Brief Title
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Official Title
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 13, 2020 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
April 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Collaborators
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled. The study will consist of two parts: Part A is dose escalation and dose expansion phase for mono-therapy, and Part B is dose escalation and dose expansion phase for combination therapy in gastric, gastroesophageal junction(G/GEJ) and biliary tract cancer, etc.
Detailed Description
There are two parts in the study. Part I is mono-therapy dose escalation and dose expansion study, and Part II is dose escalation and dose expansion study of combination therapy. The dose escalation study will be conducted utilizing 3+3 design with two dosing regimens, i.e. "once every 2 weeks (Q2W)" and "once every 3 weeks (Q3W)". After MTD/RP2D determined, three cohorts may be included in the expansion plan, with about 30 (20-40) subjects with positive CLDN18.2 expression be treated in each cohort, as shown below (during the study, the treatment cohorts may be adjusted or added based on the clinical and pre-clinical study data). Approximately 320-540 treated subjects in total

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
320 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
dose escalation Q2W
Arm Type
Experimental
Arm Description
Dosed every 2 weeks IV with TST001, multiple dose levels will be tested.
Arm Title
dose escalation Q3W
Arm Type
Experimental
Arm Description
Dosed every 3 weeks IV with TST001, multiple dose levels will be tested.
Arm Title
Cohort A
Arm Type
Experimental
Arm Description
Participants with gastric or gastroesophageal junction cancers and CLDN18.2 expression
Arm Title
Cohort B
Arm Type
Experimental
Arm Description
Participants with ductal adenocarcinoma of pancreas and CLDN18.2 expression and CLDN18.2 expression
Arm Title
Cohort E
Arm Type
Experimental
Arm Description
Participants with advanced or metastatic solid tumors other than G/GEJ adenocarcinoma and CLDN18.2 expression
Arm Title
Cohort C
Arm Type
Experimental
Arm Description
Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
Arm Title
Cohort D
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic G/GEJ adenocarcinoma
Arm Title
Cohort F
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic biliary tract cancer
Arm Title
Cohort G
Arm Type
Experimental
Arm Description
Participants with HER2 negative or unknown locally advanced or metastatic G/GEJ adenocarcinoma
Arm Title
Cohort H (TST001 plus nivolumab)
Arm Type
Experimental
Arm Description
Participants with locally advanced or metastatic G/GEJ adenocarcinoma
Intervention Type
Drug
Intervention Name(s)
TST001
Intervention Description
TST001 will be administered by specified doses on specified day
Intervention Type
Drug
Intervention Name(s)
Oxaliplatin
Intervention Description
Oxaliplatin will be administered by specified doses on specified day
Intervention Type
Drug
Intervention Name(s)
Capecitabine
Intervention Description
Capecitabine will be administered by specified doses on specified day
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Paclitaxel will be administered by specified doses on specified day
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Intervention Description
Gemcitabine will be administered by specified doses on specified day
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Intervention Description
Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Intervention Description
Nivolumab will be administered by specified doses on specified day
Primary Outcome Measure Information:
Title
Participant Safety as characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0).
Description
An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time Frame
up to 30 days following last dose.
Title
Maximum Tolerated Dose (MTD)
Description
The maximum tolerated dose (MTD) is commonly estimated to be the maximum dose that can be determined through DLT of two among 6 subjects administered with TST001 Q2W in 28 days cycles.
Time Frame
up to 28 days following first dose
Title
Maximum Tolerated Dose (MTD)
Description
The maximum tolerated dose (MTD) is commonly estimated to be the maximum dose that can be determined through DLT of two among 6 subjects administered with TST001 once every 3 weeks in 21 days cycles.
Time Frame
up to 21days following first dose
Title
Recommended Phase 2 Dose (RP2D)
Description
The RP2D will be determined during the dose expansion stage of the study. RP2D will be determined using available safety and efficacy data.
Time Frame
up to 30 days following last dose
Title
The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 Q2W in 28 days cycles during observation period
Description
DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Time Frame
up to 28 days following first dose
Title
The incidence and case number of DLT (Dose Limiting Toxicity) in subjects administered with TST001 once every 3 weeks in 21 days cycles during observation period
Description
DLT is short for Dose Limiting Toxicity. dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Time Frame
up to 21days following first dose
Title
Safety and Tolerability of TST001 in combination with other therapies, e.g. CAPOX, paclitaxel, GP, nivolumab as characterized by frequency and severity of adverse events
Description
Characterization of TST001 + CAPOX safety profile including frequency and severity of adverse events that are related to treatment.
Time Frame
Up to 30 or 90 days following last dose
Secondary Outcome Measure Information:
Title
Area under plasma concentration vs time curve (AUC) for TST001
Description
Changes in AUC over time in participants with TST001.
Time Frame
up to 30 days following last dose
Title
Peak plasma concentration (Cmax) for TST001
Description
Cmax is the maximum plasma concentration.
Time Frame
up to 30 days following last dose
Title
Time to maximum observed plasma concentration (Tmax)
Description
Tmax is the time in hrs/days it takes to reach Cmax after dosing with TST001
Time Frame
up to 30 days following last dose
Title
Terminal elimination half life (t1/2)
Description
Time for the plasma level of TST001 to decrease b y 1/2 during the terminal elimination phase.
Time Frame
up to 30 days following last dose
Title
Immunogenicity
Description
by measurement of Incidence of anti-drug antibodies (ADA)
Time Frame
up to 30 days following last dose
Title
Objective response rate (ORR)
Description
as measured by RECIST 1.1
Time Frame
up to 30 days following last dose
Title
Duration of Response (DOR)
Description
DOR is defined as the time from the date of the first response CR (complete remission)/PR (partial remission) (whichever is first recorded) to the date of radiographical progression/death or date of censoring.
Time Frame
up to 30 days following last dose
Title
Disease Control Rate
Description
DCR: CR+PR+SD
Time Frame
up to 30 days following last dose
Title
Progression free survival (PFS) and OS
Description
as measured by RECIST v1.1
Time Frame
up to 30 days following last dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subjects who meet all inclusion criteria can be enrolled into the trial: Sign the Informed Consent Form (ICF) voluntarily, understand the study and be willing and able to comply with all study procedures; Male or female ≥ 18 years at signing the ICF; Suffer from histologically confirmed locally unresectable advanced or metastatic solid tumors and meet the criteria of corresponding cohort as follows: Part I - Mono-therapy dose escalation and expansion phase: Mono-therapy dose escalation study: The subjects who have no option of or are intolerable to SOC. Mono-therapy dose expansion study: The subjects with positive CDLN18.2 expression in tumor tissue (defined as CLDN18.2 membranous staining ≥1+ in ≥10% of tumor cells by immunohistochemistry (IHC) in the central laboratory) confirmed by the central laboratory at enrollment. The dose expansion study may include the following 3 cohorts: Cohort A: Subjects with G/GEJ adenocarcinoma who have no option of or are intolerable to SOC; Cohort B: Subjects with ductal adenocarcinoma of pancreas who have no option of or are intolerable to SOC; Cohort E: Subjects with other locally advanced or metastatic solid tumors excluding G/GEJ adenocarcinoma (limited to biliary tract neoplasms, lung adenocarcinoma or colorectal cancer) who have no option of or are intolerable to SOC; Part II - Dose escalation and expansion phase for combination medication Dose escalation study of combination medication (dose escalation part): Cohort C/G: Subjects with HER2 negative or unknown G/GEJ adenocarcinoma who have not received prior systemic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled. Cohort D: The subjects with G/GEJ adenocarcinoma who have received at least prior first-line systemic chemotherapy; Cohort F: The subjects with biliary neoplasm who have not received prior systematic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled. Cohort H: The subjects with G/GEJ adenocarcinoma who have received at least prior second-line systemic chemotherapy; Dose expansion study of combination medication (dose expansion part): The subjects with positive CDLN18.2 expression in tumor tissue confirmed by the central laboratory will be enrolled as follows: Cohort C/G: Subjects with HER2 negative or unknown G/GEJ adenocarcinoma who have not received prior systemic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled. Cohort D: The subjects with G/GEJ adenocarcinoma who have received at least prior first-line systemic chemotherapy; Cohort F: The subjects with biliary neoplasm who have not received prior systematic chemotherapy. The subjects who have completed neoadjuvant or adjuvant chemotherapy within at least 6 months prior to the initial dosing of the study can be enrolled. Cohort H: The subjects with G/GEJ adenocarcinoma who have received at least prior second-line systemic chemotherapy; ECOG performance status of 0-1; Life expectancy ≥ 3 months; The results of laboratory examinations at screening must meet all the following criteria: Absolute neutrophil count (ANC) ≥ 1.5×109/L; Absolute white blood cell (WBC) count ≥2.5×109/L; Platelets ≥ 100×109/L; Haemoglobin ≥ 9 g/dL; International normalized ratio (INR) ≤ 1.5 times upper limit of normal (ULN) / or activated partial thromboplastin time (APTT) ≤ 1.5 times ULN (for the test without anticoagulant); INR ≤ 2.5 times ULN / or APTT ≤ 2.5 times ULN (for the test with anticoagulant); Total bilirubin <= 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of < 3.0 mg/dL).; AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for subjects with hepatic cancer or liver metastases); ALT/AST ≤ 3xULN regardless of liver metastasis for cohort G and H only; Albumin ≥ 30g/L; Serum creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60 ml/min (creatinine clearance rate will be calculated using Cock-croft-Gault Equation); Male and female of childbearing age should agree to take effective contraception measures (refer to Appendix 3. Contraception) from signing the ICF till at least 120 days post the last dose of TST001 and other study drugs except nivolumab; female of childbearing age should agree to take effective contraception measures (refer to Appendix 3. Contraception) from signing the ICF till at least 5 months post the last dose of nivolumab; Serum β-HCG test for women of childbearing age within 72 hours prior to the initial dosing must be negative; (For dose expansion phase only) At least one measurable lesion conforming to per RECIST v1.1; Exclusion Criteria: The subjects who meet any one of the following criteria will be excluded from participation in this study: The subjects with locally advanced or metastatic G/GEJ adenocarcinoma who are supposed to be enrolled into the combination therapy cohorts with CAPOX and CAPOX+nivolumab (Cohort C and G) have previously received systemic chemotherapy; and the subjects in the Cohort G have previously received PD1/PD-L1/CTLA4 antibody treatment. The subjects will be eligible provided that they have completed neoadjuvant or adjuvant chemotherapy at least 6 months prior to the initial dosing of the study; The subjects with locally advanced or metastatic G/GEJ adenocarcinoma who are supposed to be enrolled into the combination therapy cohort with paclitaxel (Cohort D) have previously received taxane drugs. The subjects who previously received radiotherapy within 4 weeks prior to the initial dosing of the investigational drug (the subjects who previously received local radiotherapy for bone metastases treatment within 4 weeks with the radiotherapy related AE resolved to ≤ Grade 1 will be eligible); The subjects who previously received other systematic anti-tumor drug therapies within 4 weeks or 5 half-lives prior to the initial dosing of the investigational drug (whichever is shorter); The medication (such as zoledronic acid) for bone metastases related events will not influence on the enrollment; The subjects who previously received major surgery (exclusive of aspiration biopsy) within 8 weeks prior to the initial dosing of the investigational drug, or who are expected to undergo major surgery, or who are in the conditions such as severe unhealed wound, trauma, and ulcer; The subjects who previously received targeted CLDN18.2 therapy (including CLDN18.2 monoclonal antibody, ADC, double antibody, CART); The subjects who have previous serious allergic reactions, or are intolerable to the known component of TST001 or other monoclonal antibodies (including humanized or chimeric antibodies); The subjects who are known to have immediate or delayed hypersensitivity to, be intolerable to or be forbidden from any component of the investigational drugs; The subjects who have previous serious allergic reaction or intolerance to taxane drugs (Cohort D only) or any component of CAPOX (Cohort C and G), PD1 antibody (Cohort G and H) or GP (Cohort F); The subjects in whom symptoms of brain or leptomeningeal metastases are present; The subjects with central nerve system (CNS) metastasis who meets the following conditions can be enrolled: The subjects with brain metastasis who have not received to any treatment and are asymptomatic, or who are radiologically stable for at least 8 weeks following treatment and do not require hormone or anti epilepsy treatment at least within 8 weeks; The subjects with body cavity effusion (hydrothorax, ascites and pericardial effusion) requiring local treatment or repeated drainage which is not well controlled at the discretion of the investigators; The subjects with concurrent malignant tumors within 3 years other than adequately treated cervical carcinoma in situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer with no treatment required (with or without resection), ductal carcinoma in situ of the breast, or ≤ T1 urothelial carcinoma (for the dose expansion phase only); Any adverse reactions caused by previous treatment have not resolved to ≤ Grade 1 as per CTCAE v5.0 (exclusive of alopecia and anaemia) before the initial dosing of the investigational drug. If the adverse reaction has no clinical influence, the Sponsor and investigators will decide whether the subject can be enrolled in the study after discussion. The subjects who received growth factor, transfusion or other blood products in treatment of anaemia or decreased platelet within 14 days prior to the initial dose; The subjects who experienced clinically significant cardiovascular and cerebrovascular diseases within 6 months before the initial dosing of the investigational drug, including: i. Myocardial infarction, ii. Unstable angina pectoris, iii. Cerebrovascular accident or iv. Other acute uncontrollable cardiovascular diseases; Clinically significant ventricular arrhythmia history (such as ongoing ventricular tachycardia, ventricular fibrillation and torsade de pointes); New York Heart Association (NYHA) Class III or IV congestive cardiac failure; QTc ≥470ms (female) or QTc ≥450ms (male), or medical history or family history of congenital long-QT syndrome (Naring A, 2012); The subjects with heart rhythm disorders requiring the treatment with antiarrhythmic drugs (The subjects who suffer from atrial fibrillation with heart rate controllable more than 1 month before the initial dosing of the investigational drug will be eligible); The subjects who are known to have dihydropyrimidine dehydrogenase (DPD) deficiency. (Note: DPD deficiency screening should be performed according to local requirement.) (The screening will be performed only in the subjects receiving CAPOX.) Subjects with recent gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy; The subjects who have evidenced risk of gastric haemorrhage or gastric perforation will be excluded from the study at the discretion of the investigators; The subjects with documented obstruction pyloric and persistent repeated vomiting defined as ≥ 3 episodes within 24 hours; Documented active colitis within 4 weeks prior to study entry, including infectious colitis, radiation colitis and ischemic colitis. History of ulcerative colitis or Crohn's disease; Uncontrolled diarrhea is present; The subjects who are known to have > Grade 1 peripheral sensory neuropathy, unless a lack of deep tendon reflexes is the only neurological abnormality; Active infection requiring systematically intravenous antibiotic therapy within 2 weeks prior to dosing; HIV infection history or positive HIV viral test; The subjects who are known to have the history of hepatitis C or chronic active hepatitis B; Except for: HBV virus carriers or subjects with hepatitis B infection that is stable after medications (HBV-DNA titer should be no more than 1000 copies [cps]/mL or 200 IU/mL); Patients who are not currently on viral suppressive therapy may be eligible and should be discussed with the Medical Monitor and if enrolled, antiviral therapy is required throughout study treatment. Subjects with hepatitis C infection that is stable after medications (HCV-RNA test negative); Subjects with active autoimmune disorders requiring systemic immunosuppressive therapy within the past 2 years (Subjects with type 1 diabetes mellitus (TD1M), hypothyroidism requiring hormone replacement therapy only, or skin diseases that do not require systemic treatment are eligible); Any disease requiring systemic treatment with corticosteroids (> 10 mg/day prednisone or equivalent drugs) or other immunosuppressive drugs for ≤14 days prior to the first dose of the investigational drug, except for: Adrenal replacement steroids (≤10 mg/day prednisone or equivalent drugs) Topical, ophthalmic, intra-articular, intranasal or inhaled corticosteroids with low systemic absorption Preventive corticosteroids (e.g. prevention of contrast media allergy) for short term (≤ 7 days), or corticosteroids for the treatment of non-autoimmune disorders (e.g. delayed type hypersensitivity caused by contactant); Any conditions that the investigators judge that the patient is not appropriate for PD-1 antibody treatment, including but not limited to a history of interstitial lung disease or non-infectious pneumonia, uncontrollable lung diseases, such as pulmonary fibrosis, active pneumonia, etc. (Cohort G and H); Subjects vaccinated live vaccine within 4 weeks before the first dose of the investigational drug; Pregnant or lactating women; Subject with other conditions (such as psychological, geographic or medical conditions) that do not allow them to follow the study schedule and follow-up procedures. Or the subjects who are unsuitable to be enrolled into the study at the discretion of the investigators. As of protocol version 4.2, enrollment of subjects on the combination protocol no longer requires a positive CLDN18.2 expression result, but enrolled subjects must provide sufficient formalin-fixed paraffin-embedded (FFPE) wax blocks of tumor tissue specimens or at least 10 consecutive white slices) for retrospective CLDN18.2 and PD-L1 testing. (Patients may be enrolled if they have less than 10 specimens, but not less than 7, and meet the requirements of the other inclusion criteria and receive approval from the sponsor's medical ombudsman). Other protocol defined inclusion/exclusion criteria could apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Qian Wu
Phone
860512-67079200
Email
Qian.wu@transcenta.com
First Name & Middle Initial & Last Name or Official Title & Degree
Henry Mao
Phone
860512-67079200
Email
henry.mao@transcenta.com
Facility Information:
Facility Name
The First Affiliated Hospital of Bengbu Medical College
City
Bengbu
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fuyou Zhao
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100036
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
lin Shen
Phone
010-88196340
Email
doctorshenlin@sina.cn
Facility Name
Beijing Friendship Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bangwei Cao
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lin Zhao
Facility Name
Peking University International Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Liang
Facility Name
The First Affiliated Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Zhang
Facility Name
Fujian Cancer Hospital
City
Fuzhou
State/Province
Fujian
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zengqing Guo
Facility Name
Fujian Medical University Union Hospital
City
Fuzhou
State/Province
Fujian
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chunmei Shi
Facility Name
The First Affiliated Hospital of Xiamen University
City
Xiamen
State/Province
Fujian
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiayi Li
Facility Name
The Sixth Affiliated Hospital of Sun Yat-sen University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanhong Deng
Facility Name
The People's Hospital of Guangxi Zhuang Autonomous Region
City
Guangxi
State/Province
Guangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kehe Chen
Facility Name
Hainan Provincial People's Hospital
City
Haikou
State/Province
Hainan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lin Wang
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Heibei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qingxia Fan
Facility Name
Harbin Medical University Cancer Hospital
City
Ha'erbin
State/Province
Heilongjiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuxian Bai
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ning li
Facility Name
Hubei Cancer Hospital
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huiting Xu
Facility Name
Zhongnan Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fuxiang Zhou
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xianli Yin
Facility Name
Xiangya Hospital, Central South University
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shan Zeng
Facility Name
Suzhou Municipal Hospital
City
Suzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Feng Guo
Facility Name
The Second Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhixiang Zhuang
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liang Han
Facility Name
The Second Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hua Wang
Facility Name
Jilin Cancer Hospital
City
Chang chun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Cheng
Facility Name
The First Hospital of Jilin University
City
Chang chun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Li
Facility Name
The First Affiliated Hospital of Jinzhou Medical University
City
Jinzhou
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhitu Zhu
Facility Name
Liaoning Cancer Hospital & Institute
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jingdong Zhang
Facility Name
The First Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiujuan Qu
Facility Name
Jinan Central Hospital
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meili Sun
Facility Name
Linyi Cancer Hospital
City
Linyi
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianhua Shi
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaochun Zhang
Facility Name
Fudan University Shanghai Cance Center
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
guo weijian
Email
guoweijian1@hotmail.com
Facility Name
Zhongshan Hospital Fudan University
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tianshu Liu
Facility Name
West China Hospital, Sichuan University
City
Chendu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dan Cao
Facility Name
Sichuan Cancer Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jin Lu
Facility Name
Tianjin Medical University Cancer Institute & Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongli Li
Facility Name
Tianjin Medical University General Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diansheng Zhong
Facility Name
First Affiliated Hospital of Zhejiang University
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
nong xu
Phone
0571-87236560
Email
xunongclinicltrial@126.com
Facility Name
The Second Affiliated Hospital of Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Yuan
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haijun Zhong

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs